- Home
- IMAB vs CBUS Comparison
IMAB vs CBUS Comparison
Compare IMAB & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- CBUS
- Stock Information
- Founded
- IMAB 2014
- CBUS 2010
- Country
- IMAB United States
- CBUS United States
- Employees
- IMAB N/A
- CBUS N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- CBUS Agricultural Chemicals
- Sector
- IMAB Health Care
- CBUS Industrials
- Exchange
- IMAB Nasdaq
- CBUS Nasdaq
- Market Cap
- IMAB 73.9M
- CBUS 65.3M
- IPO Year
- IMAB 2020
- CBUS 2017
- Fundamental
- Price
- IMAB $2.50
- CBUS $1.50
- Analyst Decision
- IMAB Strong Buy
- CBUS Strong Buy
- Analyst Count
- IMAB 2
- CBUS 3
- Target Price
- IMAB $5.50
- CBUS $22.00
- AVG Volume (30 Days)
- IMAB 1.0M
- CBUS 709.5K
- Earning Date
- IMAB 05-15-2025
- CBUS 08-07-2025
- Dividend Yield
- IMAB N/A
- CBUS N/A
- EPS Growth
- IMAB N/A
- CBUS N/A
- EPS
- IMAB N/A
- CBUS N/A
- Revenue
- IMAB N/A
- CBUS $4,751,000.00
- Revenue This Year
- IMAB N/A
- CBUS $32.97
- Revenue Next Year
- IMAB N/A
- CBUS $66.40
- P/E Ratio
- IMAB N/A
- CBUS N/A
- Revenue Growth
- IMAB N/A
- CBUS 104.78
- 52 Week Low
- IMAB $0.60
- CBUS $1.40
- 52 Week High
- IMAB $3.08
- CBUS $10.77
- Technical
- Relative Strength Index (RSI)
- IMAB 67.42
- CBUS 37.01
- Support Level
- IMAB $2.29
- CBUS $1.40
- Resistance Level
- IMAB $2.69
- CBUS $1.58
- Average True Range (ATR)
- IMAB 0.35
- CBUS 0.22
- MACD
- IMAB 0.00
- CBUS -0.09
- Stochastic Oscillator
- IMAB 64.53
- CBUS 5.43
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.